FAS and FASL variations in outcomes of tobacco- and alcohol-related head and neck squamous cell carcinoma patients

Radiotherapy and cisplatin lead to cell killing in head and neck squamous cell carcinoma patients, but adverse events and response to treatment are not the same in patients with similar clinicopathological aspects. The aim of this prospective study was to evaluate the roles of TP53 c.215G > C, FAS c.-671A > G, FAS c.-1378G > A, FASL c.-844 C > T, CASP3 c.-1191A > G, and CASP3 c.-182-247G > T single nucleotide variants in toxicity, response rate, and survival of cisplatin chemoradiation-treated head and neck squamous cell carcinoma patients. Genomic DNA was analyzed by polymerase chain reaction for genotyping. Differences between groups of patients were analyzed by chi-square test or Fisher’s exact test, multiple logistic regression analysis, and Cox hazards model. One hundred nine patients with head and neck squamous cell carcinoma were enrolled in study. All patients were smokers and/or alcoholics. Patients with FAS c.-671GG genotype, FAS c.-671AG or GG genotype, and FASL c.-844CC genotype had 5.52 (95% confidence interval (CI): 1.42–21.43), 4.03 (95% CI: 1.51–10.79), and 5.77 (95% CI: 1.23–27.04) more chances of presenting chemoradiation-related anemia of grades 2–4, lymphopenia of grade 3 or 4, and ototoxicity of all grades, respectively, than those with the remaining genotypes. FAS c.-671GG genotype was also seen as an independent predictor of shorter event-free survival (hazard ratio (HR): 2.05; P = 0.007) and overall survival (HR: 1.83; P = 0.02) in our head and neck squamous cell carcinoma patients. These findings present, for the first time, preliminary evidence that inherited abnormalities in apoptosis pathway, related to FAS c.-671A > G and FASL c.-844 C > T single nucleotide variants, can alter toxicity and survival of tobacco- and alcohol-related head and neck squamous cell carcinoma patients homogeneously treated with cisplatin chemoradiation.

[1]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[2]  S. Tabassum,et al.  Single-Nucleotide Polymorphisms of FAS and FASL Genes and Risk of Idiopathic Aplastic Anemia , 2018, Immunological investigations.

[3]  I. Louro,et al.  Frequency of HPV in oral cavity squamous cell carcinoma , 2018, BMC Cancer.

[4]  R. K. Galimudi,et al.  Polymorphic variants of Caspase genes (8 & 3) in the risk prediction of Coronary Artery Disease. , 2017, Gene.

[5]  J. Hess,et al.  Epidemiology and Molecular Biology of Head and Neck Cancer , 2017, Oncology Research and Treatment.

[6]  Y. Li,et al.  Association of genetic variants with tumor HPV16 status and survival in squamous cell carcinoma of the oropharynx. , 2016, Oral oncology.

[7]  C. Ramos,et al.  XPD c.934G>A polymorphism of nucleotide excision repair pathway in outcome of head and neck squamous cell carcinoma patients treated with cisplatin chemoradiation , 2016, Oncotarget.

[8]  Rui Chen,et al.  FAS rs2234767 and rs1800682 polymorphisms jointly contributed to risk of colorectal cancer by affecting SP1/STAT1 complex recruitment to chromatin , 2016, Scientific Reports.

[9]  Q. Wei,et al.  Apoptotic variants as predictors of risk of oropharyngeal cancer recurrence after definitive radiotherapy , 2015, International journal of cancer.

[10]  S. Bhattacharya,et al.  Prevention of myelosuppression and genotoxicity induced by cisplatin in murine bone marrow cells: effect of an organovanadium compound vanadium(III)-l-cysteine. , 2015, Mutagenesis.

[11]  C. Dinh,et al.  Molecular regulation of auditory hair cell death and approaches to protect sensory receptor cells and/or stimulate repair following acoustic trauma , 2015, Front. Cell. Neurosci..

[12]  Hun Myoung Park,et al.  Hypothesis Testing and Statistical Power of a Test , 2015 .

[13]  A. Roco,et al.  Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy? , 2014, Front. Genet..

[14]  Xiuqin Jiang,et al.  Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer , 2014, Cancer biology & therapy.

[15]  H. Liu,et al.  Multiple Analytical Approaches Demonstrate a Complex Relationship of Genetic and Nongenetic Factors with Cisplatin- and Carboplatin-Induced Nephrotoxicity in Lung Cancer Patients , 2014, BioMed research international.

[16]  F. Xia,et al.  Ionizing radiation-induced DNA damage, response, and repair. , 2014, Antioxidants & redox signaling.

[17]  P. Brennan,et al.  Human papillomavirus (HPV) 16 and the prognosis of head and neck cancer in a geographical region with a low prevalence of HPV infection , 2014, Cancer Causes & Control.

[18]  Y. Wettergren,et al.  Folate Levels and Polymorphisms in the Genes MTHFR, MTR, and TS in Colorectal Cancer , 2014, Clinical Medicine Insights. Oncology.

[19]  D. Hayes,et al.  Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  J. Thariat,et al.  The impact of pharmacogenetics on radiation therapy outcome in cancer patients. A focus on DNA damage response genes. , 2012, Cancer treatment reviews.

[21]  A. Azad,et al.  Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival , 2011, Clinical Cancer Research.

[22]  Ananya Choudhury,et al.  Recurrence patterns of locally advanced head and neck squamous cell carcinoma after 3D conformal (chemo)-radiotherapy , 2011, Radiation oncology.

[23]  J. Lissowska,et al.  Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. , 2011, International journal of epidemiology.

[24]  M. Kris,et al.  Consensus recommendations for the prevention of vomiting and nausea following high-emetic-risk chemotherapy , 2011, Supportive Care in Cancer.

[25]  J. Yokota,et al.  Association of DNA repair gene polymorphisms with response to platinum-based doublet chemotherapy in patients with non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  W. Westra,et al.  Comparison of human papillomavirus in situ hybridization and p16 immunohistochemistry in the detection of human papillomavirus‐associated head and neck cancer based on a prospective clinical experience , 2010, Cancer.

[27]  A. Khrunin,et al.  Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients , 2010, The Pharmacogenomics Journal.

[28]  M. Wiedmann,et al.  A non‐apoptotic role for Fas/FasL in erythropoiesis , 2009, FEBS letters.

[29]  Hui-Ping Zhao,et al.  CASP3 Polymorphisms and Risk of Squamous Cell Carcinoma of the Head and Neck , 2008, Clinical Cancer Research.

[30]  E. D. De Capitani,et al.  Influence of p53 codon 72 exon 4, GSTM1, GSTT1 and GSTP1*B polymorphisms in lung cancer risk in a Brazilian population. , 2008, Lung cancer.

[31]  S. Kam,et al.  Identification of polymorphisms in the Caspase‐3 gene and their association with lung cancer risk , 2008, Molecular carcinogenesis.

[32]  M. Peter,et al.  The CD95 Receptor: Apoptosis Revisited , 2007, Cell.

[33]  L. Rybak,et al.  Mechanisms of cisplatin-induced ototoxicity and prevention , 2007, Hearing Research.

[34]  W. Tan,et al.  Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer , 2005, Journal of Medical Genetics.

[35]  K. Rajewsky,et al.  T Cell–specific Ablation of Fas Leads to Fas Ligand–mediated Lymphocyte Depletion and Inflammatory Pulmonary Fibrosis , 2004, The Journal of experimental medicine.

[36]  K. Shah,et al.  Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[37]  Z. Siddik,et al.  Cisplatin: mode of cytotoxic action and molecular basis of resistance , 2003, Oncogene.

[38]  M. Murphy,et al.  The codon 72 polymorphic variants of p53 have markedly different apoptotic potential , 2003, Nature Genetics.

[39]  G. Cooper,et al.  A Novel Polymorphic CAAT/Enhancer-Binding Protein β Element in the FasL Gene Promoter Alters Fas Ligand Expression: A Candidate Background Gene in African American Systemic Lupus Erythematosus Patients1 , 2003, The Journal of Immunology.

[40]  M. Sheard.  Ionizing radiation as a response‐enhancing agent for CD95‐mediated apoptosis , 2001, International journal of cancer.

[41]  J. Edmonds,et al.  Evaluation of a new Apo-1/Fas promoter polymorphism in rheumatoid arthritis and systemic lupus erythematosus patients. , 1999, Rheumatology.

[42]  R. Hayes,et al.  Tobacco and alcohol use and oral cancer in Puerto Rico , 1999, Cancer Causes & Control.

[43]  G. Stassi,et al.  Apoptotic role of Fas/Fas ligand system in the regulation of erythropoiesis. , 1999, Blood.

[44]  D. Israeli,et al.  p53 Activates the CD95 (APO-1/Fas) Gene in Response to DNA Damage by Anticancer Drugs , 1998, The Journal of experimental medicine.

[45]  J. Verweij,et al.  Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  W. Hrushesky,et al.  Cisplatin-associated anemia: an erythropoietin deficiency syndrome. , 1995, The Journal of clinical investigation.

[47]  L. Hutchins,et al.  Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  J. Bergerat,et al.  Cisplatin-induced anemia: a potential interference with iron metabolism at erythroid progenitors level. , 1990, Anti-cancer drugs.

[49]  L. Green,et al.  Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence , 1986, Medical care.

[50]  B. Esmaeli,et al.  Change in Eyelid Carcinoma T Category With Use of the 8th Versus 7th Edition of the American Joint Committee on Cancer: Cancer Staging Manual. , 2019, Ophthalmic plastic and reconstructive surgery.

[51]  J. Grandis,et al.  WHO classification of head and neck tumours , 2017 .

[52]  Ruud H. Brakenhoff,et al.  The molecular biology of head and neck cancer , 2011, Nature Reviews Cancer.

[53]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[54]  R. Macklis,et al.  Radiation Oncology BioMed Central Review The impact of functional imaging on radiation medicine , 2008 .

[55]  J. Ensley,et al.  An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.